Qiangpu Biotechnology Company was established in 2014, dedicating itself to hidden drug mechanisms that most companies overlook as its core focus for cancer research and development. The founder of the company is a clinical oncologist with over 30 years of clinical experience in cancer treatment. Leading a professional, independent R&D team, the founder continuously and diligently conducts in-depth research in anti-cancer drugs and cell therapy technologies across five key directions: rapid clinical entry, synthetic lethal formulations, wide applicability, reasonable pricing, and exclusive patents, aiming to benefit patients and continuously seek new directions for the future of cancer treatment.

Through keen clinical observations and based on patients' needs and feedback, the company continuously develops innovative therapies that can be immediately applied in clinical practice. These are repeatedly validated using patented technology platforms in biochemistry and immunology. Currently, the company has two major innovative development directions in cancer treatment R&D, namely 505(b)(2) new drug development and cell therapy, and has obtained patents in various countries with its independently developed technologies.

The members of the R&D team mostly come from clinical backgrounds in hospitals. The relevant pharmacological technologies are inherited from patient treatment experience and developed independently; thus, during the development process, costs can be controlled while developing innovative therapies. From the experience of actual face-to-face contact with patients in clinical settings, we firmly believe that drug development must first and foremost focus on practical application. Considering the benefits to the users of the medication and maintaining positive interactions with patients are where true treatment really begins.